e-Therapeutics Plc - Company Profile
Powered by 
All the data and insights you need on e-Therapeutics Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date e-Therapeutics Plc Strategy Report
- Understand e-Therapeutics Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
e-Therapeutics Plc (e-Therapeutics) is a drug discovery and development company with a focus on discovering novel therapeutic approaches and mechanisms for the treatment of various diseases such as cancer, diabetes, and neurodegenerative disease. It carries out its work by integrating proprietary databases and computational tools that use network analysis, machine learning, Al, data mining, and optimization. The company harnesses its two proprietary, productive, and unique technology platforms, Network-Driven Drug Discovery (NDD) and Genome Associated Network Interactions (GAINs), for the target of validation and novel discovery. e-Therapeutics has a research partnership with Novo Nordisk for developing therapeutics for type 2 diabetes. e-Therapeutics is headquartered in London, the UK.
Headquarters
United Kingdom
Address
Floor 4, 4 Kingdom Street, Paddington Central, London, England, W26BD
Website
www.etherapeutics.co.uk
Telephone
44 20 45518888
No of Employees
38
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ETX (LON)
Revenue (2023)
$585,500
-0.4%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
-2.5%
(2023 vs 2022)
Market Cap*
$66.8M
Net Profit Margin (2023)
XYZ
-3.0%
(2023 vs 2022)
* As of and is in US$
e-Therapeutics Plc premium industry data and analytics
Products and Services
| Products |
|---|
| Proprietary technology platforms: |
| Network-Driven Drug Discovery (NDD) platform. |
| Genome Associated Network Interactions (GAINs) platform. |
Competitor Comparison
| Key Parameters | e-Therapeutics Plc | Alliance Pharma Plc | Oxford BioMedica Plc | Domainex Ltd | Sentinel Oncology Ltd |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom | United Kingdom | United Kingdom |
| City | London | Chippenham | Oxford | Saffron Walden | Cambridge |
| State/Province | England | England | England | England | England |
| No. of Employees | 38 | 249 | 891 | 76 | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ali Mortazavi | Chief Executive Officer | Senior Management | 2020 | - |
| Trevor Jones | Chairman | Non Executive Board | 2021 | - |
| Timothy Bretherton | Chief Financial Officer | Senior Management | 2023 | - |
| Jonny Wray | Chief Technology Officer | Senior Management | 2011 | - |
| Stephanie Maley | Chief People Officer | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer